No Data
No Data
Express News | HC Wainwright & Co. Reiterates Buy on Equillium, Maintains $5 Price Target
Equillium Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/17/2024 223.62% HC Wainwright & Co. → $5 Reiterates Buy → Buy 04/02/2024 223.62% HC Wainwright & Co. $4
Buy Rating Affirmed for Equillium on Milestones and Financial Prospects
Express News | Equillium Surpasses Interim Enrollment Target For Phase 3 EQUATOR Study Of Itolizumab II Acute Graft-Versus-Host Disease
Express News | Equillium Inc - Delivery of Interim Data Review to Ono Pharmaceutical Co. Ltd. (Ono) Expected During Q3 Will Trigger Ono's Option Exercise Period
Express News | Equillium Announces Interim Enrollment Achieved in Phase 3 Equator Study of Itolizumab in Acute Graft-Versus-Host Disease